The effect of chloroquine treatment in malignant astrocytomas on prognosis

Objective & Hypothesis:To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas (MAs).

📊

Key Findings & Data:Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine, from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy.

💡

Conclusion & Impact:Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAs.

🔬Design:Research Article

📍Scope:2003 Verileri

⚙️Variables:Key words: Chloroquine treatment · malignant astrocytomas · prognosis

Abstract

To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas (MAs). Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine, from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy. Chloroquine treatment was started on a daily dose of 150 mg, additional to the patients' radiotherapy and chemotherapy protocol, and was continued throughout the 43-month surveillance period. A control group was formed of 81 patients with MA after the craniotomy. Results: While the mean survival time of the patients who were treated with chloroquine was found to be 15 months, during the observation period 7 of these patients (18.9%) were alive throughout. In the control group, 20 patients (35.1%) were alive throughout the observation period and their mean survival time was 17 months. There were no statistical differences between the control and chloroquine groups (P > 0.05). Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAs.

Özet

To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas (MAs). Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine, from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy. Chloroquine treatment was started on a daily dose of 150 mg, additional to the patients' radiotherapy and chemotherapy protocol, and was continued throughout the 43-month surveillance period. A control group was formed of 81 patients with MA after the craniotomy. Results: While the mean survival time of the patients who were treated with chloroquine was found to be 15 months, during the observation period 7 of these patients (18.9%) were alive throughout. In the control group, 20 patients (35.1%) were alive throughout the observation period and their mean survival time was 17 months. There were no statistical differences between the control and chloroquine groups (P > 0.05). Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAs.

Keywords

Key words: Chloroquine treatment malignant astrocytomas prognosis antimutagenic effect

🔖

Cite This Article

BULUT, T., EKİCİ, M. A., TUCER, B., BAŞARSLAN, S. K. (2013). The effect of chloroquine treatment in malignant astrocytomas on prognosis. Turkish Journal of Medical Sciences, Cilt: 43 - Sayı: 5, 782–789. https://ajindex.com/articles/400877

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (11)

Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635–44.
Kim EL, Wüstenberg R, Rübsam A, Schmitz-Salue C, Warnecke G, Bücker EM et al. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol 2010; 12: 389–400.
Kokunai T, Tamaki N, Matsumoto S. ACNU-resistant mutants of 9L rat glioma cell line. Isolation and preliminary characterization of these subclones. J Neurosurg 1985; 63: 583– Cohen A, Modan M. Some epidemiologic aspects of neoplastic disease in Israeli immigrant population III. Brain tumors. Cancer 1968; 22: 1323–8.
Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337–43.
Kleihues P, Cavenee WK, editors. Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press; 2000.
Sawaya R, Hammound M, Schoppa D, Hess KR, Shi WM, Wildrick DM. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998; 42: 1044–56. Bach MK Reduction in the frequency of mutation to resistance to cytarabine in L1210 murine leukemic cells by treatment with quinacrine hydrochloride. Cancer Res 1969; 29: 1881–5.
Hoffman GR, Deschenes SM, Manyin T, Fuchs RP. Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli. Mutat Res 1996; 351: 33– Spriggs DR, Sherman ML, Imamura K, Mohri M, Rodriguez C, Robbins G et al. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res 1990; 50: 7101–7.
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350–4.
Pfab R, Schachtschabel DO, Kern HF. Ultrastructural studies of the effect of x-rays and quinacrine (Atebrin) or chloroquine (Resochin) — alone or in combination — on Harding-Passey melanoma cells in monolayer culture. Strahlentherapie 1985; 161: 711–8.
Jensen PB, Sİrensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 1994; 54: 2959–63.
Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlys